2024-04-09 10:48:41 ET
Summary
- Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024.
- The global Dravet Syndrome market is expected to reach $1 billion by 2036.
- Results from the phase 3 Skyway study, using soticlestat for the treatment of patients with Lennox-Gastaut Syndrome, expected by or before September 2024.
- The global Lennox-Gastaut Syndrome market is expected to reach $1 billion by 2030.
Ovid Therapeutics Inc. ( OVID ) is gearing up for major inflection points in Q3 of 2024. That is, it intends to release results from two phase 3 studies, using soticlestat for the treatment of patients with two rare forms of epileptic disorders, by or before September 2024. These two disorders being targeted with the use of this drug are Lennox-Gastaut Syndrome [LGS] and Dravet Syndrome [DS]....
Read the full article on Seeking Alpha
For further details see:
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024